Management of Medullary Thyroid Cancer.
CEA
Calcitonin
MEN
Medullary thyroid cancer
RET
Journal
Endocrinology and metabolism clinics of North America
ISSN: 1558-4410
Titre abrégé: Endocrinol Metab Clin North Am
Pays: United States
ID NLM: 8800104
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
entrez:
6
2
2019
pubmed:
6
2
2019
medline:
31
5
2019
Statut:
ppublish
Résumé
Medullary thyroid cancer (MTC) is rare but aggressive. It can be cured only if intrathyroid at diagnosis. MTC can be sporadic (75%) or familial (25%) and the 2 forms are distinguished by RET mutations analysis. Calcitonin is the specific serum marker; its doubling time is the most important prognostic factor for survival and progression; 30% of MTC patients have distant metastases at diagnosis and, when progressing, systemic therapy with vandetanib or cabozantinib should be considered. Before starting this treatment, the possibility of using a local treatment should be evaluated to delay systemic therapy. A multidisciplinary team should care for these patients.
Identifiants
pubmed: 30717909
pii: S0889-8529(18)30593-0
doi: 10.1016/j.ecl.2018.11.006
pii:
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Calcitonin
9007-12-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
285-301Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.